

Clinical Trial Protocol

Iranian Registry of Clinical Trials

06 Jun 2026

Effect of red beetroot on metabolic factors in subjects with pre-diabetes

Protocol summary

Study aim

To examine the effect of consuming red beetroot powder on metabolic factors in people with pre-diabetes.

Design

Clinical trial with a control group and parallel design, double-blind, randomized, phase 3 on 74 patients. The WinPepi software was used for randomization.

Settings and conduct

Beetroot has the potential to be effective and therapeutic in people with pre-diabetes. People with pre-diabetes who refer to Isfahan Endocrine and Metabolism Research Center and meet the inclusion criteria will be invited to participate in this research. After obtaining informed consent, people will be asked to refer to the Endocrine and Metabolism Research Center in a fasting state of at least 8 hours during their next visit (first visit), and fasting and two-hour blood glucose samples, as well as blood and urine samples necessary for Biochemical measurements will be collected. Besides, information on anthropometrics, demographics, blood pressure, general characteristics, food intake and physical activity will be collected. At the end of week 12 (second visit), all measurements from the first visit will be repeated.

During the study, the participants, the trained questioner, and the outcome examiner will be blinded to the type of intervention. For blinding, the sachets of both intervention and placebo groups will be identical in terms of shape, color, weight and other physical characteristics.

Participants/Inclusion and exclusion criteria

Inclusion criteria: people with prediabetes aged 20-80 years old. Non-Inclusion criteria: use of any anti-diabetic agent except metformin; pregnant or lactating women.

Intervention groups

Intervention: Red beetroot powder. Placebo: Rice powder

Main outcome variables

Main outcomes: 2-hour blood glucose level; fasting blood sugar; fasting insulin; hemoglobin A1C; homeostatic model assessment for insulin resistance; the quantitative insulin-sensitivity check index

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20221220056876N1**

Registration date: **2023-01-02, 1401/10/12**

Registration timing: **prospective**

Last update: **2023-01-02, 1401/10/12**

Update count: **0**

Registration date

2023-01-02, 1401/10/12

Registrant information

Name

Elham Hosseini

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3792 3183

Email address

hosseini@res.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-01-21, 1401/11/01

Expected recruitment end date

2024-04-20, 1403/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of red beetroot on metabolic factors in subjects

with pre-diabetes

Public title

Effect of red beetroot in subjects with pre-diabetes

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Age 20-80 years old BMI 18-35 kg/m²

Exclusion criteria:

People with type 1, type 2, or gestational diabetes mellitus Use of any anti-diabetic agent except metformin Taking medication that affects glucose metabolism such as glucocorticoids, less than eight weeks before the start of the study Receiving growth hormone in less than six months before the start of the study Allergy to beetroot consumption A smoker or a history of smoking and alcohol consumption in the previous two years History of cardiovascular diseases (open heart surgery, cardiac congestion, heart failure, and uncontrolled blood pressure), liver cirrhosis/liver transplant, and/or kidney disease (CKD) History of inflammatory diseases such as rheumatoid arthritis A history of hypothyroidism or hyperthyroidism History of suffering from severe digestive diseases or mental illnesses Having often physical activity (more than 5 hours a week) Taking antioxidant supplements or hormonal treatments 4 weeks before the study Pregnant or lactating women

Age

From **20 years** old to **80 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size

Target sample size: **74**

Randomization (investigator's opinion)

Randomized

Randomization description

In this study, the participants are randomly assigned to two groups of consuming beetroot powder (intervention) or placebo group. For randomization, the WinPepi software was used and the participants of each group (intervention and placebo) were placed in two strata (metformin users and non-users). The number of participants in each stratum was determined based on the prevalence of metformin use in prediabetic people. In the output of the software, the sequence of participants in two strata was determined, and in each stratum, the participants have been assigned to the intervention or placebo group. After randomization, the list of generated codes was deleted.

Blinding (investigator's opinion)

Double blinded

Blinding description

For blinding, intervention sachets will be similar to placebo sachets in terms of shape, texture, color, weight,

and other physical characteristics. The intervention sachets contain beetroot powder and the placebo sachets contain rice powder, which has been prepared at the same color as the beetroot powder using an approved food color.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

1

Registry name

Secondary trial Id

Registration date

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Isfahan University of Medical Sciences

Street address

Hezar Jerib

City

Isfahan

Province

Isfahan

Postal code

8174673461

Approval date

2022-08-22, 1401/05/31

Ethics committee reference number

IR.ARI.MUI.REC.1401.087

Health conditions studied

1

Description of health condition studied

Prediabetes

ICD-10 code

R73.02

ICD-10 code description

Impaired glucose tolerance (oral)

Primary outcomes

1

Description

2-hour blood glucose

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

2

Description

Fasting blood sugar

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

3

Description

Fasting insulin

Timepoint

At the baseline and after 12 weeks

Method of measurement

The enzyme-linked immunosorbent assay

4

Description

Hemoglobin A1C

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

5

Description

Homeostatic model assessment for insulin resistance

Timepoint

At the baseline and after 12 weeks

Method of measurement

Calculated by formula

6

Description

The quantitative insulin-sensitivity check index

Timepoint

At the baseline and after 12 weeks

Method of measurement

Calculated by formula

Secondary outcomes

1

Description

Triglyceride

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

2

Description

Total cholesterol

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

3

Description

Low density lipoprotein

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

4

Description

High density lipoprotein

Timepoint

At the baseline and after 12 weeks

Method of measurement

Enzyme calorimetry method

5

Description

High sensitivity-C Reactive Protein

Timepoint

At the baseline and after 12 weeks

Method of measurement

The enzyme-linked immunosorbent assay

6

Description

Glutathione

Timepoint

At the baseline and after 12 weeks

Method of measurement

The enzyme-linked immunosorbent assay

7

Description

Total antioxidant capacity

Timepoint

At the baseline and after 12 weeks

Method of measurement

The enzyme-linked immunosorbent assay

8

Description

Total oxidative stress

Timepoint

At the baseline and after 12 weeks

Method of measurement

The enzyme-linked immunosorbent assay

9

Description

Alanine transaminase

Timepoint

At the baseline and after 12 weeks

Method of measurement
Enzyme calorimetry method

10

Description
Aspartate aminotransferase
Timepoint
At the baseline and after 12 weeks
Method of measurement
Enzyme calorimetry method

11

Description
Alkaline Phosphatase
Timepoint
At the baseline and after 12 weeks
Method of measurement
Enzyme calorimetry method

12

Description
Gamma-glutamyltransferase
Timepoint
At the baseline and after 12 weeks
Method of measurement
Enzyme calorimetry method

13

Description
The Fibrosis-4 score
Timepoint
At the baseline and after 12 weeks
Method of measurement
Calculated by formula

14

Description
Serum creatinine
Timepoint
At the baseline and after 12 weeks
Method of measurement
Kinetic Jaffe calorimetry

15

Description
Urine creatinine
Timepoint
At the baseline and after 12 weeks
Method of measurement
Kinetic Jaffe calorimetry

16

Description
Blood urea nitrogen
Timepoint
At the baseline and after 12 weeks
Method of measurement

Enzyme calorimetry method

17

Description
Urine microalbumin
Timepoint
At the baseline and after 12 weeks
Method of measurement
The enzyme-linked immunosorbent assay

Intervention groups

1

Description
Intervention group: Red beetroot powder prepared by Pak Shilan Negin Salamat private company located in Chaharmahal and Bakhtiari province, producing all kinds of fruit powder, summer vegetables, and dried vegetables, 7 grams twice a day (14 grams daily) for 12 weeks. (3 months), it is eaten with yogurt, salad, or a meal during lunch and dinner.

Category
Treatment - Other

2

Description
Control group: Rice powder prepared by Pak Shilan Negin Salamat private company located in Chaharmahal and Bakhtiari province, producing all kinds of fruit powder, summer vegetables, and dried vegetables, 7 grams twice a day (14 grams daily) for 12 weeks (3 months), it is eaten with yogurt, salad, or a meal during lunch and dinner.

Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Isfahan Endocrine and Metabolism Research Center
Full name of responsible person
Mansour Siavash
Street address
Khorram Street
City
Isfahan
Province
Isfahan
Postal code
8187698191
Phone
+98 31 3335 9933
Email
emrc@mui.ac.ir
Web page address
<https://emrc.mui.ac.ir/en/node/1120>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Gholamreza Askari

Street address

Hezar jerib Ave.

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 7898

Fax**Email**

research@mui.ac.ir

Web page address

<https://research.mui.ac.ir/fa/sitemap>

Grant name

570000056

Grant code / Reference number

240112

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Elham Hosseini

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

hezar jerib Ave.

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3792 3183

Email

hosseini@res.mui.ac.ir

Web page address

<https://nfsrc.mui.ac.ir/fa/sitemap>

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Elham Hosseini

Position

Assistant professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Hezar Jerib Ave.

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3792 3183

Email

hosseini@res.mui.ac.ir

Web page address

<https://nfsrc.mui.ac.ir/fa/sitemap>

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Elham Hosseini

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

□ Nutrition and Food Security Research Center, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Hezar Jerib Ave.

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3792 3183

Fax**Email**

hosseini@res.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data from this research can be shared after de-identifying individuals.

When the data will become available and for how long

3 months after the results are published.

To whom data/document is available

All researchers.

Under which criteria data/document could be used

Data requests will be considered only after the publication of results.

From where data/document is obtainable

The main research executor: Elham Hosseini E-mail address: hosseini@res.mui.ac.ir

What processes are involved for a request to access data/document

After the publication of the results, people intending to use data collected in this research can make their request by submitting their proposal to the main executor. If the proposal is accepted by the executor, the data will be provided to the requester.

Comments